Altria Group Reports Q3 Beats, but Sales Slow

Altria Group (NYSE: MO) met adjusted earnings expectations in Q3 while delivering a revenue beat that caught investors’ attention. The stock traded near $62.19 at the 9:00 AM ET filing, having drifted lower in recent weeks from its mid-$60s peak. Management raised the lower end of full-year guidance and expanded its buyback program, signaling confidence in the business despite ongoing headwinds in traditional tobacco.

Altria reported $6.07 billion in quarterly revenue, crushing the $5.31 billion consensus estimate by 14.4% but representing a 3% year-over-year decline. Yet this headline strength deserves scrutiny. The company’s reported gross profit and operating income surged dramatically year over year, but this reflects accounting adjustments related to the Horizon subsidiary rather than underlying operational momentum. Core segment performance tells a different story.

Smokeable products revenue fell 8.2% in domestic shipments. Oral tobacco products declined 4.6% to $689 million. Both of Altria’s primary businesses contracted, a reminder that the company operates in a structurally declining market. The revenue beat came primarily from higher adjusted operating companies income, a measure of profitability that benefits from cost discipline and fewer shares outstanding rather than volume or pricing strength.

Adjusted diluted EPS came in at $1.45, matching consensus expectations exactly. On a year-over-year basis, this represented 3.6% growth from $1.38 in Q3 2024. The modest increase reflects two tailwinds. First, the Optimize and Accelerate cost-savings initiative is delivering results, supporting profitability even as volumes decline. Second, aggressive share repurchases reduce the share count, lifting per-share metrics mechanically.

The company expanded its buyback authorization from $1 billion to $2 billion, with the program expiring December 31, 2026. Combined with a 3.9 percent dividend increase to $4.24 per share, management is prioritizing cash returns to shareholders. This capital allocation strategy works when the stock trades at a reasonable valuation and cash generation remains strong. At a 6.45 percent dividend yield and 11.99 trailing P/E, both conditions appear intact.

Management raised the lower end of 2025 adjusted EPS guidance to $5.37 from the prior $5.19 base, implying full-year growth of 3.5 to 5.0 percent. This modest upward revision reflects confidence in execution but signals no acceleration in underlying business trends. CEO Billy Gifford described the quarter as building “significant momentum,” though the language remained measured.

The company is advancing smoke-free initiatives, with Horizon having submitted FDA applications for Ploom and Marlboro heated tobacco sticks. Success here matters for long-term positioning, but near-term earnings will continue to depend on managing decline in traditional products while capturing pricing where possible.

• Adjusted EPS: $1.45 (met $1.45 estimate); up 3.6% year over year

• Revenue: $6.07B (beat $5.31B estimate by 14.4%); up 13.6% year over year

• Operating Income: $8.33B (up 164.2% year over year)

• Net Income: $5.83B (up 154.3% year over year)

• Smokeable Products Revenue: $5.39B (down 2.8%)

• Oral Tobacco Revenue: $689M (down 4.6%)

The operating income and net income gains reflect the Horizon accounting treatment rather than organic business acceleration. Look instead at segment performance to understand core momentum. Both are contracting, which is typical for this business but worth acknowledging directly.

Gifford emphasized “continued progress” across the business and highlighted the guidance raise as evidence of confidence. The CFO pointed to strong operating cash generation and disciplined cost management. Neither executive signaled aggressive growth or expansion; the tone was one of steady execution in a mature, declining industry.

The company faces ongoing regulatory and tariff headwinds. Management acknowledged these risks but did not quantify their potential impact on 2025 results. You’ll want to listen during the earnings call for any color on how tariffs might affect pricing or margins in coming quarters.

Altria’s story hinges on three factors. First, can the company maintain pricing discipline as volumes continue to decline? Second, will smoke-free products gain meaningful traction and offset traditional tobacco losses? Third, how will tariffs and regulatory enforcement affect profitability? The stock has pulled back from its August high, trading about 5.5 percent below its 50-day moving average. If the company can demonstrate that cost savings and capital returns are sustainable, the valuation remains reasonable for dividend-focused investors. If segment declines accelerate or pricing power weakens, the 6.45% yield may not be enough to offset fundamental deterioration.